Deadline Approaches for ADMA Biologics Securities Class Action: Investor Action Required

Attention ADMA Biologics Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, is urging ADMA Biologics, Inc. investors to take action regarding a securities class action lawsuit. The deadline to seek the lead plaintiff role is August 10, 2026, following serious allegations against the company concerning false representation and undisclosed financial practices.

Background of the Case

Investors who acquired ADMA Biologics securities between August 9, 2024, and March 25, 2026, are advised to consider their options. The lawsuit reflects significant concerns about the company's internal practices and public reporting. Specifically, it is alleged that ADMA Biologics failed to disclose material information, including engaging in undisclosed related-party transactions, and misrepresenting its revenue growth through misleading accounting practices.

The impact of these allegations became evident when on March 24, 2026, a research firm known as Culper Research published a report revealing that ADMA Biologics had engaged in channel stuffing to inflate its revenue figures, creating a façade of business growth that was not substantiated. As a result, the company’s stock plummeted by nearly 29% in just two days.

Understanding the Role of Lead Plaintiff

In a class action lawsuit, the lead plaintiff is an investor chosen by the court to represent the interests of all class members. This role involves oversight of the case and collaboration with legal counsel. If you are an ADMA Biologics investor who suffered losses, you might be eligible to assume this role and influence outcomes in the litigation. To be considered for the lead plaintiff position, potential candidates must file their motion by the looming deadline.

What Investors Should Do Now

For investors impacted by the allegations against ADMA Biologics, it is crucial to review transaction records, preserve documentation, and evaluate legal rights. Engaging with Faruqi & Faruqi is recommended to explore all avenues for participation in the class action and whether seeking lead plaintiff status or simply joining as a class member is in your best interest.

The firm's extensive experience in securities litigation has led to substantial recoveries for investors in past cases, presenting a favorable option for those affected by ADMA Biologics' alleged misconduct.

Seeking Support

If you believe you have been wronged as an investor in ADMA Biologics, you are encouraged to reach out to Faruqi & Faruqi for a consultation free of charge. Their team is ready to discuss your situation, your rights, and potential next steps. Don't leave your chances for recovery to chance; contact them directly at 877-247-4292 or visit their website for detailed information on how to proceed.

Conclusion

The upcoming deadline for legal action against ADMA Biologics is a critical moment for investors seeking to protect their interests. As the allegations of misleading practices loom large, now is the time to act decisively. Stay informed, engage with legal specialists, and potentially recover losses sustained due to deceptive practices. Your investment rights are crucial; ensure they are safeguarded by taking proactive steps before it is too late.